Maravai LifeSciences Holdings, Inc. MRVI R2K
Company Overview
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Recent Developments
- Dec 2025 Revenue of $185.74M (-28.3% YoY); net profit $-130.77M.
- Trailing 12 Months Year-on-year growth — revenue +40.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.44% |
| 1 Year: | 40.50% |
Stock Price Performance
| 1 Year: | +143.82% |
| 6 Months: | +65.65% |
| 3 Months: | +112.75% |
| 1 Month: | +24.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)73.11 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MRVI Maravai LifeSciences Holdings, Inc. R2K | 6.51 | -9.17 | $960.27M | 0.00% | -29.66% | -40.98% | 4.44% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.98M | 46.91M | 87.86M | 148.21M | 217.78M | 204.81M | 244.29M | 242.73M | 191.26M | 79.03M | 68.91M | 66.86M | 64.18M | 69.42M | 69.03M | 46.85M | 47.40M | 41.63M | 65.84M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.23M | 7.72M | - | 5.66M | 33.70M |
| Operating Income | 34.82M | 8.12M | 45.72M | 91.19M | 153.53M | 155.38M | 167.37M | 180.70M | 116.90M | 2.53M | -11.61M | -15.42M | -18.86M | -13.44M | -165.61M | -49.16M | -66.28M | -41.03M | -2.16M |
| Net Income | 23.39M | 1.42M | 38.95M | 23.10M | 49.14M | 53.96M | 66.86M | 71.24M | 44.47M | -67.00K | -6.54M | -6.46M | -12.08M | -9.79M | -97.07M | -29.95M | -39.59M | -25.56M | -3.73M |
| Diluted EPS | 0.09 | 0.00 | 0.12 | 0.24 | 0.44 | 0.44 | 0.50 | 0.53 | 0.34 | 0.00 | -0.05 | -0.05 | -0.09 | -0.07 | -0.68 | -0.21 | -0.27 | -0.18 | -0.02 |
| R&D Expense | 3.74M | 1.60M | 1.87M | 2.16M | 1.93M | 1.95M | 3.69M | 4.27M | 5.39M | 4.14M | 4.19M | 4.35M | 5.03M | 4.92M | 4.70M | 4.89M | 4.88M | 3.84M | 3.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 143.14M | 284.10M | 799.24M | 883.00M | 288.94M | 259.19M | 185.74M |
| Gross Profit | - | - | - | - | 140.20M | 108.31M | 33.99M |
| Operating Income | 23.99M | 119.90M | 554.64M | 574.22M | -31.65M | -235.62M | -215.27M |
| Net Income | -4.47M | 88.97M | 182.04M | 220.21M | -119.03M | -144.85M | -130.77M |
| Diluted EPS | -0.03 | 2.36 | 1.56 | 1.67 | -0.90 | -1.05 | -0.90 |
| R&D Expense | 3.63M | 9.30M | 15.22M | 18.37M | 17.28M | 19.22M | 17.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Oct 2020 | Dec 2020 | Dec 2021 | Jan 2022 | Dec 2022 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.27B | 1.92B | - | 2.28B | 1.49B | 1.44B | 1.28B | 1.01B | 770.58M |
| Total Equity | 144.63M | - | 88.51M | 315.50M | - | 545.22M | 416.75M | 434.73M | 344.90M | 325.29M | 212.38M |
| Cash & Equivalents | - | - | - | - | - | 632.14M | 574.96M | 573.17M | 578.16M | 322.40M | 216.89M |
| Long Term Debt | - | 400.00M | 528.61M | 524.59M | 544.00M | 522.00M | 518.71M | 517.08M | 516.28M | 290.49M | 286.33M |
| Total Liabilities | - | - | 1.12B | 1.37B | - | 1.38B | 697.57M | 671.26M | 665.56M | 431.04M | 397.87M |
| Current Liabilities | - | - | 130.78M | 93.78M | - | 110.14M | 87.47M | 68.62M | 63.71M | 56.97M | 44.92M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 24.11M | 152.19M | 368.57M | 535.98M | 126.22M | 7.46M | -57.57M |
| Investing Cash Flow | -17.15M | 6.07M | 105.66M | -267.61M | -122.31M | -24.32M | -31.41M |
| Financing Cash Flow | -4.17M | 53.21M | -159.05M | -187.50M | -61.09M | -235.71M | -16.50M |
| Capital Expenditure | -17.15M | -25.41M | -14.85M | -17.09M | -65.55M | -29.66M | -13.15M |
| Free Cash Flow | 6.97M | 126.78M | 353.72M | 518.89M | 60.67M | -22.19M | -70.72M |
| Share Buybacks | 0 | 33.66M | 0 | 0 | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 48.5% | 41.8% | 18.3% |
| Operating Margin % | 16.8% | 42.2% | 69.4% | 65.0% | -11.0% | -90.9% | -115.9% |
| Net Margin % | -3.1% | 31.3% | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| ROE % | -3.1% | 100.5% | 57.7% | 40.4% | -28.6% | -44.5% | -61.6% |
| ROCE % | - | 10.5% | 30.4% | 26.4% | -2.3% | -24.8% | -29.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | GTCR, LLC | 13.66% | 20.15M | $120.19M |
| 2 | Braidwell LP | 6.94% | 10.24M | $61.08M |
| 3 | Blackrock Inc. | 6.34% | 9.35M | $55.74M |
| 4 | 12 West Capital Management Lp | 4.92% | 7.26M | $43.31M |
| 5 | Mackenzie Financial Corporation | 4.28% | 6.31M | $37.62M |
| 6 | Vanguard Capital Management LLC | 3.69% | 5.45M | $32.51M |
| 7 | Renaissance Technologies, LLC | 2.89% | 4.26M | $25.44M |
| 8 | Tejara Capital Ltd | 2.37% | 3.50M | $20.85M |
| 9 | Monaco Asset Management SAM | 2.32% | 3.42M | $20.41M |
| 10 | Morgan Stanley | 2.25% | 3.32M | $19.80M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MRVI
MRVI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5xT2hORVNkQXB0YTlob3pIM3RubklIYWFtTGhLeEg4X2hMazJTckNHdnJqN29jVkN3Y3QybjQ2TTJhNGNzV2d3a1RPNnpDVzlKajdWbDcxMmRRbFlodkZ0dzZFYjROSTJXc3ZPRFhQNjY2SFZfR1ZZX2lR?oc=5" target="_blank">MRV…
Maravai Lifesciences (MRVI) CEO reports 29,250-share tax withholding event - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOTTFOcFQ0VlNfVHRHZ1Q4RnhpUy00RDRZdGFwYjAtemtNV3U1Z2Vjc0E5c1VVelJjRXp5YWdEQmo4YllqYjZNVkRvM2hLa25zMFlVTkF1T1N6Slg1U0xkV25pSHJ1V19sbklnckZTSzhodGtyc1JGaG9EMFpWbE1PeG1ZMnpqM01LeXR3WT…
How The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value Targets - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcFBCcW9XZ0tveU1xbnZoam8tcmhjQjRzR2VnRGtEUEhVVk5hSDR6Y191MlRJbUYtUXNPWW5ZUlhDZ25ITEpyaUpPdDNCaHczeU9KdWxXTWdvRHVibFZ5ekQzRUVvaFNfdmlEYUVWWm95dXc3Z0hrSkhtcGFJMm5rbjlPeVB6d1c1bUh3c3…
Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxOQ2taSnc5Vmc5N2ZkZnM0TkowUVFBRzUtTDhPLXRBeDV0cjdZVnYzQUcydnpZNG5LbmlRZnRoV0FDWlZDdm1Qa01GbHFPRUdLRThXVE9HNEIyb3NsSGxWeWNKcnByR2U1SDNCWmVaRVY2UEtzMlBBVzJaT3ZOcHlPcFZkM21GRGJaaG9ISX…
Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQYzh6Tmw3VHNoNk5Xelg1Sk1rNmRpQnVTbm96Wm43UjBWTENqQTdYR1F6bFMtbWhvOWl2alV1cFdJSXFYVTVmZ29JSkFmc0dfQmpHWnpVdHE5OFlUejRwblJ6Vl9wT0N2V3IyejdOS2RXbXVyYzd2aG95VWdsaVFHZDFsNkJHT2VQMF9tV1…
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOdUV6ZnRYMFJSazNYZGVaOEtxOF9rb0djQ0xfU0FfLW9PY0pQYXFHdGJsbTBQVkNiMk45d3ZfT1dXdDBfekxCLWNCckxEMkMxRVltU0w5TW01T0FOVjFGQjBCQlhybm5UTlJCaXREbGFNeWYxamE4NDRsN2s5VDc4a0x3ZEV2SUpyLVVCU1…
MRVI — Frequently Asked Questions
What is the current share price of Maravai LifeSciences Holdings, Inc. (MRVI)?
As of 2026-07-14 21:23 PDT, Maravai LifeSciences Holdings, Inc. (MRVI) trades at $6.51 on NasdaqGS. Its 52-week range is $2.02 to $6.51.
What is the market capitalisation of MRVI?
Maravai LifeSciences Holdings, Inc. (MRVI) has a market capitalisation of $960.27M on NasdaqGS.
What is the P/E ratio of MRVI?
MRVI trades at a trailing price-to-earnings (P/E) ratio of -9.17. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.47.
What is the return on equity (ROE) of MRVI?
MRVI has a return on equity (ROE) of -40.98%. Its return on capital employed (ROCE) is -29.66%.
Is MRVI a good stock to buy?
This page provides a data-driven analysis of Maravai LifeSciences Holdings, Inc. (MRVI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.